JP2006249089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006249089A5 JP2006249089A5 JP2006065731A JP2006065731A JP2006249089A5 JP 2006249089 A5 JP2006249089 A5 JP 2006249089A5 JP 2006065731 A JP2006065731 A JP 2006065731A JP 2006065731 A JP2006065731 A JP 2006065731A JP 2006249089 A5 JP2006249089 A5 JP 2006249089A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- imidazo
- pyridin
- carbonyl
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyridin-1-yl Chemical group 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- HZVLFTCYCLXTGV-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 HZVLFTCYCLXTGV-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66059205P | 2005-03-11 | 2005-03-11 | |
| US60/660,592 | 2005-03-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006249089A JP2006249089A (ja) | 2006-09-21 |
| JP2006249089A5 true JP2006249089A5 (enExample) | 2009-04-16 |
| JP5069415B2 JP5069415B2 (ja) | 2012-11-07 |
Family
ID=36649530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006065731A Expired - Lifetime JP5069415B2 (ja) | 2005-03-11 | 2006-03-10 | 結晶形態のイミダゾール誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7960407B2 (enExample) |
| EP (1) | EP1861400B1 (enExample) |
| JP (1) | JP5069415B2 (enExample) |
| KR (1) | KR100911073B1 (enExample) |
| CN (1) | CN101137656B (enExample) |
| AR (1) | AR055567A1 (enExample) |
| AT (1) | ATE469150T1 (enExample) |
| AU (1) | AU2006221699A1 (enExample) |
| BE (1) | BE2018C028I2 (enExample) |
| BR (1) | BRPI0608819B8 (enExample) |
| CA (1) | CA2600510C (enExample) |
| DE (1) | DE602006014516D1 (enExample) |
| ES (1) | ES2344310T3 (enExample) |
| FR (1) | FR18C1028I2 (enExample) |
| IL (1) | IL185145A0 (enExample) |
| IN (1) | IN2014DN09939A (enExample) |
| MX (1) | MX2007011110A (enExample) |
| NL (1) | NL300944I2 (enExample) |
| PL (1) | PL1861400T3 (enExample) |
| RU (1) | RU2357968C1 (enExample) |
| TW (1) | TW200643021A (enExample) |
| WO (1) | WO2006095268A1 (enExample) |
| ZA (1) | ZA200707568B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009295308A1 (en) | 2008-09-25 | 2010-04-01 | Merck Canada Inc. | Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists |
| CA2754702C (en) * | 2009-04-22 | 2016-06-07 | Yukinori Take | Selective ep4 antagonistic substance for treatment of cancer |
| BR112012020236A2 (pt) | 2010-02-22 | 2016-05-17 | Raqualia Pharma Inc | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero |
| RU2451680C1 (ru) | 2011-02-21 | 2012-05-27 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство |
| RU2464042C1 (ru) * | 2011-03-31 | 2012-10-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| KR102239641B1 (ko) * | 2013-03-19 | 2021-04-13 | 에스크엣 인크. | 연골질환 치료에서의 ep4 수용체 길항제의 용도 |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| CN105939713A (zh) * | 2014-03-06 | 2016-09-14 | 阿莱塔纳治疗学股份有限公司 | 格拉匹纶组合物及其使用方法 |
| CA2997697A1 (en) * | 2014-03-06 | 2015-09-11 | Aratana Therapeutics, Inc. | Crystalline forms of grapiprant |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| AU2019255196A1 (en) | 2018-04-16 | 2020-11-12 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
| CA3107023A1 (en) * | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Ep4 inhibitors and synthesis thereof |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US11459331B2 (en) | 2019-01-30 | 2022-10-04 | Avista Pharma Solutions, Inc. | Chemical compounds |
| EP3917935A4 (en) | 2019-01-30 | 2022-11-16 | Avista Pharma Solutions, Inc. | SYNTHESIS PROCESS AND NEW INTERMEDIATES |
| US11254675B2 (en) | 2019-08-12 | 2022-02-22 | Cadila Healthcare Limited | Process for preparation of grapiprant |
| WO2021226162A1 (en) | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Ep4 antagonists and their use in the treatment of proliferative diseases |
| KR20240042400A (ko) | 2021-07-30 | 2024-04-02 | 라퀄리아 파마 인코포레이티드 | 결정질 형태 |
| CN116478155B (zh) * | 2022-01-17 | 2025-06-13 | 洛阳惠中兽药有限公司 | 一种格拉匹伦及其中间体的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| IL164263A0 (en) * | 2002-04-12 | 2005-12-18 | Pfizer | Use of ep4 receptor ligands on the treatment of il-6 involved diseases |
-
2006
- 2006-03-01 RU RU2007133802/04A patent/RU2357968C1/ru active
- 2006-03-01 IN IN9939DEN2014 patent/IN2014DN09939A/en unknown
- 2006-03-01 EP EP06710609A patent/EP1861400B1/en not_active Expired - Lifetime
- 2006-03-01 DE DE602006014516T patent/DE602006014516D1/de not_active Expired - Lifetime
- 2006-03-01 CN CN2006800079642A patent/CN101137656B/zh not_active Expired - Lifetime
- 2006-03-01 KR KR1020077020701A patent/KR100911073B1/ko not_active Expired - Lifetime
- 2006-03-01 AU AU2006221699A patent/AU2006221699A1/en not_active Abandoned
- 2006-03-01 WO PCT/IB2006/000754 patent/WO2006095268A1/en not_active Ceased
- 2006-03-01 BR BRPI0608819A patent/BRPI0608819B8/pt active IP Right Grant
- 2006-03-01 US US11/908,163 patent/US7960407B2/en active Active
- 2006-03-01 PL PL06710609T patent/PL1861400T3/pl unknown
- 2006-03-01 ES ES06710609T patent/ES2344310T3/es not_active Expired - Lifetime
- 2006-03-01 AT AT06710609T patent/ATE469150T1/de not_active IP Right Cessation
- 2006-03-01 CA CA2600510A patent/CA2600510C/en not_active Expired - Lifetime
- 2006-03-01 MX MX2007011110A patent/MX2007011110A/es active IP Right Grant
- 2006-03-09 AR ARP060100886A patent/AR055567A1/es unknown
- 2006-03-09 TW TW095108018A patent/TW200643021A/zh unknown
- 2006-03-10 JP JP2006065731A patent/JP5069415B2/ja not_active Expired - Lifetime
-
2007
- 2007-08-09 IL IL185145A patent/IL185145A0/en unknown
- 2007-09-03 ZA ZA200707568A patent/ZA200707568B/xx unknown
-
2018
- 2018-07-03 FR FR18C1028C patent/FR18C1028I2/fr active Active
- 2018-07-05 NL NL300944C patent/NL300944I2/nl unknown
- 2018-07-05 BE BE2018C028C patent/BE2018C028I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2600510A1 (en) | Crystal forms of an imidazole derivative | |
| RU2014105881A (ru) | Ансольваты солей норибогаина | |
| RU2008143362A (ru) | Сокристаллическая форма производного с-гликозида c l-пролином | |
| JP2010514806A5 (enExample) | ||
| ME02275B (me) | Polimorfni oblik rotigotina | |
| JP2009536176A5 (enExample) | ||
| RU2598606C3 (ru) | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она | |
| JP2011528658A5 (enExample) | ||
| JP2018168191A5 (enExample) | ||
| JP2010514807A5 (enExample) | ||
| JP2012533565A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JP2016503010A5 (enExample) | ||
| JP2012502037A5 (enExample) | ||
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| RU2009133262A (ru) | Нападизилатная соль антагониста мускаринового мз-рецептора | |
| HRP20171511T1 (hr) | Ivabradin-hidroklorid, oblik iv | |
| JP2012512158A5 (enExample) | ||
| JP2022163049A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JP2020536893A5 (enExample) | ||
| JP2015522037A5 (enExample) | ||
| JP2010515682A5 (enExample) | ||
| JP2011527687A5 (enExample) | ||
| MX2009008463A (es) | Formulaciones biodisponibles de compuestos heterociclicos. |